FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the

OMB APPROVAL OMB Number: N BENEFICIAL OWNERSHIP

Estimated average burden hours per response: 0.5

5. Relationship of Reporting Person(s) to Issuer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

Name and Address of Reporting Person* PARVEN ALVIN S						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]								eck all applic X Directo Officer	tionship of Reportin all applicable) Director Officer (give title below)		on(s) to Issu 10% Ow Other (s) below)	ner	
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE					11	3. Date of Earliest Transaction (Month/Day/Year) 11/09/2010										Filing		Jisabla	
(Street) CHESHI (City)		tate)	· · · · · · · · · · · · · · · · · · ·				4. If Amendment, Date of Original Filed (Month/Day/Year) ative Securities Acquired, Disposed of, or Benefic								dividual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			action	tion 2A. Deeme Execution y/Year) if any		A. Deemed xecution Date,		3.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a		5. Amou Securition	nt of 6. 0 es For ally (D) Following (I) (rm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										V	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			ilisu. 4)	
Common Stock, par value \$.0001 per share 11/09/2				9/2010	010			M		11,818	A	\$9.87	17	,881		D			
Common Stock, par value \$.0001 per share 11/09/2					9/2010	.010			S		11,818	D	\$72.32	6,	063		D		
		-	Fable II -								osed of, convertil			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Option to Purchase Common Stock	\$9.87	11/09/2010			S			11,818	03/09/20	06	12/09/2015	Common Stock, par value \$.0001 per share	11,818	\$0	3,182		D		

Explanation of Responses:

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$72.16 - \$72.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

/s/ Alvin Parven

11/12/2010

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.